Polkowska-Kramek Aleksandra, Begier Elizabeth, Bruyndonckx Robin, Liang Caihua, Beese Caroline, Brestrich Gordon, Tran Thao Mai Phuong, Nuttens Charles, Casas Maribel, Bayer Lea Johanna, Huebbe Bennet, Ewnetu Worku Biyadgie, Agudelo Juan Luis Ramirez, Gessner Bradford D, von Eiff Christof, Rohde Gernot
P95 Pharmacovigilance and Epidemiology Services, Leuven, Belgium.
Pfizer Inc, Dublin, Ireland.
Infect Dis Ther. 2024 Apr;13(4):845-860. doi: 10.1007/s40121-024-00951-0. Epub 2024 Mar 23.
Respiratory syncytial virus (RSV) burden in adults is underestimated mainly due to unspecific symptoms and limited standard-of-care testing. We estimated the population-based incidence of hospitalization and mortality attributable to RSV among adults with and without risk factors in Germany.
Weekly counts of hospitalizations and deaths for respiratory, cardiovascular, and cardiorespiratory diseases were obtained (Statutory Health Insurance database, 2015-2019). A quasi-Poisson regression model was fitted to estimate the number of hospitalizations and deaths attributable to RSV as a function of periodic and aperiodic time trends, and viral activity while allowing for potential overdispersion. Weekly counts of RSV and influenza hospitalizations in children < 2 years and adults ≥ 60 years, respectively, were used as viral activity indicators. Models were stratified by age group and risk status (defined as presence of selected comorbidities).
Population-based RSV-attributable hospitalization incidence rates were high among adults ≥ 60 years: respiratory hospitalizations (236-363 per 100,000 person-years) and cardiorespiratory hospitalizations (584-912 per 100,000 person-years). RSV accounted for 2-3% of all cardiorespiratory hospitalizations in this age group. The increase in cardiorespiratory hospitalization risk associated with underlying risk factors was greater in 18-44 year old persons (five to sixfold higher) than in ≥ 75 year old persons (two to threefold higher).
This is a first model-based study to comprehensively assess adult RSV burden in Germany. Estimated cardiorespiratory RSV hospitalization rates increased with age and were substantially higher in people with risk factors compared to those without risk factors. Our study indicates that RSV, like other respiratory viruses, contributes to both respiratory and cardiovascular hospitalizations. Effective prevention strategies are needed, especially among older adults ≥ 60 years and among adults with underlying risk factors.
成人呼吸道合胞病毒(RSV)负担被低估,主要是因为症状不具特异性且标准护理检测有限。我们估计了德国有和没有风险因素的成年人中,基于人群的RSV所致住院率和死亡率。
获取了呼吸、心血管和心肺疾病的每周住院和死亡人数(法定健康保险数据库,2015 - 2019年)。拟合了一个准泊松回归模型,以估计作为周期性和非周期性时间趋势以及病毒活动函数的RSV所致住院和死亡人数,同时考虑潜在的过度离散。分别将2岁以下儿童和60岁及以上成年人中RSV和流感住院的每周人数用作病毒活动指标。模型按年龄组和风险状态(定义为存在选定的合并症)分层。
在60岁及以上成年人中,基于人群的RSV所致住院发病率很高:呼吸住院(每10万人年236 - 363例)和心肺住院(每10万人年584 - 912例)。RSV占该年龄组所有心肺住院的2 - 3%。18 - 44岁人群中与潜在风险因素相关的心肺住院风险增加幅度(高五到六倍)大于75岁及以上人群(高两到三倍)。
这是第一项基于模型的全面评估德国成人RSV负担的研究。估计的心肺RSV住院率随年龄增加,有风险因素的人群比无风险因素的人群高得多。我们的研究表明,RSV与其他呼吸道病毒一样,会导致呼吸和心血管住院。需要有效的预防策略,特别是在60岁及以上的老年人和有潜在风险因素的成年人中。